// App-Quantinova.ai

: Predicting Response of CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL) in ACIT001/EXC002, a Phase Ib Clinical Trial

Researchers

Presenter

  • Bindu Thapa

Principal Investigators

  • Carina Debes-Marun

  • Zack M. Breckenridge

  • Irwindeep Sandhu

  • Andrew Daly

  • Faisal Khan

  • Michael P. Chu

Medical Centers

  • Alberta Precision Labs/University of Calgary, Calgary, Canada

  • Cross Cancer Institute, Edmonton, Canada

  • Department of Oncology, Cross Cancer Institute, Edmonton, Canada

  • University of Alberta, Edmonton, Canada

  • Tom Baker Cancer Center, Calgary, CAN

  • Cross Cancer Institute, University of Alberta, Edmonton, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Non-Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Hodgkin's Lymphoma

  • Lymphomas

Biomarkers

  • Breakpoint Cluster Region

  • Coxsackie Virus And Adenovirus Receptor

  • Glycosylphosphatidylinositol

  • Fc gamma RIIIa

  • Human leukocyte antigen A2

Drug/Treatment

  • Interferon Gamma

Outcome

  • N/A

Study Design

  • Efficacy

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved